Claire Troakes

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3252875/publications.pdf

Version: 2024-02-01

104	9,754	47006	42399
papers	citations	47 h-index	92 g-index

109	109	109	13890
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
2	Multisystem screening reveals <scp>SARSâ€CoV</scp>â€2 in neurons of the myenteric plexus and in megakaryocytes. Journal of Pathology, 2022, 257, 198-217.	4.5	16
3	Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nature Communications, 2022, 13, 1362.	12.8	34
4	Axonal injury is detected by Î²APP immunohistochemistry in rapid death from head injury following road traffic collision. International Journal of Legal Medicine, 2022, 136, 1321-1339.	2.2	3
5	Invited Review: The spectrum of neuropathology in COVIDâ€19. Neuropathology and Applied Neurobiology, 2021, 47, 3-16.	3.2	99
6	Plasma p-tau231: a new biomarker for incipient Alzheimerâ€™s disease pathology. Acta Neuropathologica, 2021, 141, 709-724.	7.7	285
7	Spinal cord injury as an indicator of abuse in forensic assessment of abusive head trauma (AHT). International Journal of Legal Medicine, 2021, 135, 1481-1498.	2.2	8
8	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
9	The histone modification H3K4me3 is altered at the ANK1 locus in Alzheimer's disease brain. Future Science OA, 2021, 7, FSO665.	1.9	10
10	A HML6 endogenous retrovirus on chromosome 3 is upregulated in amyotrophic lateral sclerosis motor cortex. Scientific Reports, 2021, 11, 14283.	3.3	13
11	Cytoplasmic TDP-43 is involved in cell fate during stress recovery. Human Molecular Genetics, 2021, 31, 166-175.	2.9	15
12	SCFD1 expression quantitative trait loci in amyotrophic lateral sclerosis are differentially expressed. Brain Communications, 2021, 3, fcab236.	3.3	14
13	Astrocytic Câ€“Xâ€“C motif chemokine ligand-1 mediates Î²-amyloid-induced synaptotoxicity. Journal of Neuroinflammation, 2021, 18, 306.	7.2	16
14	Validation of the Movement Disorder Society Criteria for the Diagnosis of 4â€Repeat Tauopathies. Movement Disorders, 2020, 35, 171-176.	3.9	37
15	Disruption of endoplasmic reticulum-mitochondria tethering proteins in post-mortem Alzheimer's disease brain. Neurobiology of Disease, 2020, 143, 105020.	4.4	41
16	Frequency and methylation status of selected retrotransposition competent L1 loci in amyotrophic lateral sclerosis. Molecular Brain, 2020, 13, 154.	2.6	7
17	Plasma p-tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8Âyears prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathologica, 2020, 140, 267-278.	7.7	209
18	The Neuropathological Diagnosis of Alzheimerâ€™s Diseaseâ€”The Challenges of Pathological Mimics and Concomitant Pathology. Brain Sciences, 2020, 10, 479.	2.3	22

#	Article	IF	Citations
19	The Increased Densities, But Different Distributions, of Both C3 and S100A10 Immunopositive Astrocyte-Like Cells in Alzheimerâ€™s Disease Brains Suggest Possible Roles for Both A1 and A2 Astrocytes in the Disease Pathogenesis. Brain Sciences, 2020, 10, 503.	2.3	43
20	Clinical Conditions â€œSuggestive of Progressive Supranuclear Palsyâ€â€”Diagnostic Performance. Movement Disorders, 2020, 35, 2301-2313.	3.9	22
21	Plasma pâ€tau181 accurately predicts Alzheimerâ€™s disease pathology at least 8 years prior to postâ€mortem and improves the clinical characterisation of cognitive decline. Alzheimer's and Dementia, 2020, 16, e047539.	0.8	2
22	Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathologica, 2020, 140, 99-119.	7.7	210
23	Bridging integrator 1 protein loss in Alzheimerâ€™s disease promotes synaptic tau accumulation and disrupts tau release. Brain Communications, 2020, 2, .	3.3	18
24	Copathology in Progressive Supranuclear Palsy: Does It Matter?. Movement Disorders, 2020, 35, 984-993.	3.9	48
25	Symmetric dimethylation of poly-GR correlates with disease duration in C9orf72 FTLD and ALS and reduces poly-GR phase separation and toxicity. Acta Neuropathologica, 2020, 139, 407-410.	7.7	36
26	Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies. Acta Neuropathologica Communications, 2020, 8, 5.	5.2	27
27	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathologica, 2019, 138, 795-811.	7.7	50
28	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Communications, 2019, 7, 5.	5.2	125
29	Heterogeneous Nuclear Ribonucleoprotein E2 (hnRNP E2) Is a Component of TDP-43 Aggregates Specifically in the A and C Pathological Subtypes of Frontotemporal Lobar Degeneration. Frontiers in Neuroscience, 2019, 13, 551.	2.8	13
30	Transcriptomic analysis of probable asymptomatic and symptomatic alzheimer brains. Brain, Behavior, and Immunity, 2019, 80, 644-656.	4.1	72
31	Parallel profiling of DNA methylation and hydroxymethylation highlights neuropathology-associated epigenetic variation in Alzheimerâ€™s disease. Clinical Epigenetics, 2019, 11, 52.	4.1	84
32	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Movement Disorders, 2019, 34, 1228-1232.	3.9	93
33	Genome-wide DNA methylation profiling identifies convergent molecular signatures associated with idiopathic and syndromic autism in post-mortem human brain tissue. Human Molecular Genetics, 2019, 28, 2201-2211.	2.9	70
34	The Psychiatric Risk Gene NT5C2 Regulates Adenosine Monophosphate-Activated Protein Kinase Signaling and Protein Translation in Human Neural Progenitor Cells. Biological Psychiatry, 2019, 86, 120-130.	1.3	42
35	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
36	Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. Journal of Neural Transmission, 2019, 126, 327-337.	2.8	33

#	Article	IF	Citations
37	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
38	No Effect of Genome-Wide Significant Schizophrenia Risk Variation at the <i>DRD2</i> Locus on the Allelic Expression of <i>DRD2</i> in Postmortem Striatum. Molecular Neuropsychiatry, 2019, 5, 212-217.	2.9	4
39	Frequency and signature of somatic variants in 1461 human brain exomes. Genetics in Medicine, 2019, 21, 904-912.	2.4	20
40	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
41	A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases. Neurobiology of Aging, 2019, 74, 70-76.	3.1	58
42	Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. Neurobiology of Aging, 2019, 73, 229.e5-229.e9.	3.1	16
43	<scp>APOE</scp> Îµ4 is also required in <scp>TREM</scp>2 R47H variant carriers for Alzheimer's disease to develop. Neuropathology and Applied Neurobiology, 2019, 45, 183-186.	3.2	12
44	Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 813-816.	1.9	17
45	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
46	Elevated DNA methylation across a 48â€‰kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2018, 14, 1580-1588.	0.8	138
47	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron, 2018, 97, 1268-1283.e6.	8.1	517
48	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
49	A feedback loop between dipeptide-repeat protein, TDP-43 and karyopherin-Î± mediates C9orf72-related neurodegeneration. Brain, 2018, 141, 2908-2924.	7.6	75
50	A histone acetylome-wide association study of Alzheimerâ€™s disease identifies disease-associated H3K27ac differences in the entorhinal cortex. Nature Neuroscience, 2018, 21, 1618-1627.	14.8	138
51	Schizophrenia-associated methylomic variation: molecular signatures of disease and polygenic risk burden across multiple brain regions. Human Molecular Genetics, 2017, 26, ddw373.	2.9	74
52	ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiology of Aging, 2017, 51, 178.e1-178.e9.	3.1	86
53	Aluminium in brain tissue in familial Alzheimerâ€™s disease. Journal of Trace Elements in Medicine and Biology, 2017, 40, 30-36.	3.0	182
54	Mitochondrial DNA point mutations and relative copy number in 1363 disease and control human brains. Acta Neuropathologica Communications, 2017, 5, 13.	5.2	83

#	Article	IF	Citations
55	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Movement Disorders, 2017, 32, 995-1005.	3.9	121
56	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders, 2017, 32, 853-864.	3.9	1,402
57	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Science Translational Medicine, 2017, 9, .	12.4	129
58	Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinsonâ€™s disease brain. Acta Neuropathologica, 2017, 134, 113-127.	7.7	78
59	Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. Genome Research, 2017, 27, 165-173.	5.5	44
60	C9orf72 poly GA RAN-translated protein plays a key role in amyotrophic lateral sclerosis via aggregation and toxicity. Human Molecular Genetics, 2017, 26, 4765-4777.	2.9	64
61	Unusual neuropathological features and increased brain aluminium in a resident of Camelford, UK. Neuropathology and Applied Neurobiology, 2017, 43, 537-541.	3.2	8
62	Clusterin expression is upregulated following acute head injury and localizes to astrocytes in old head injury. Neuropathology, 2017, 37, 12-24.	1.2	24
63	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
64	The Identification of Aluminum in Human Brain Tissue Using Lumogallion and Fluorescence Microscopy. Journal of Alzheimer's Disease, 2016, 54, 1333-1338.	2.6	48
65	Genomeâ€wide significant schizophrenia risk variation on chromosome 10q24 is associated with altered cisâ€regulation of BORCS7, AS3MT, and NT5C2 in the human brain. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 806-814.	1.7	41
66	Alzheimer-related decrease in CYFIP2 links amyloid production to tau hyperphosphorylation and memory loss. Brain, 2016, 139, 2751-2765.	7.6	52
67	Extended post-mortem delay times should not be viewed as a deterrent to the scientific investigation of human brain tissue: a study from the Brains for Dementia Research Network Neuropathology Study Group, UK. Acta Neuropathologica, 2016, 132, 753-755.	7.7	18
68	In vitro prion-like behaviour of TDP-43 in ALS. Neurobiology of Disease, 2016, 96, 236-247.	4.4	118
69	NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1037-1042.	21.4	218
70	P1â€155: Postâ€Mortem Brain Tissue Characterisation of Inflammatory and Pathological Hallmarks of Alzheimerâ€™s Disease During Disease Progression. Alzheimer's and Dementia, 2016, 12, P462.	0.8	0
71	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	3.1	37
72	Variation in 5-hydroxymethylcytosine across human cortex and cerebellum. Genome Biology, 2016, 17, 27.	8.8	83

#	Article	IF	Citations
73	Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimerâ€™s disease brain. Acta Neuropathologica Communications, 2016, 4, 34.	5.2	100
74	Tissue-specific patterns of allelically-skewed DNA methylation. Epigenetics, 2016, 11, 24-35.	2.7	32
75	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. Neurobiology of Aging, 2016, 38, 214.e7-214.e10.	3.1	78
76	Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDPâ€43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathology and Applied Neurobiology, 2016, 42, 242-254.	3.2	61
77	Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease. Neurobiology of Aging, 2016, 37, 45-46.	3.1	8
78	Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. Acta Neuropathologica Communications, 2016, 4, 18.	5.2	46
79	Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci. Nature Neuroscience, 2016, 19, 48-54.	14.8	306
80	P1-211: Genetic influences on amyloid angiopathy and white matter pathology in familial Alzheimer's disease: A comparison of app and PSEN1 mutations. , 2015, 11, P431-P431.		0
81	ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation. Acta Neuropathologica Communications, 2015, 3, 62.	5.2	22
82	A comparison of mitochondrial DNA isolation methods in frozen post-mortem human brain tissueâ€”applications for studies of mitochondrial genetics in brain disorders. BioTechniques, 2015, 59, 241-246.	1.8	17
83	Gammaâ€synuclein pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 29-37.	3.7	21
84	Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimerâ€™s disease. Molecular Brain, 2015, 8, 6.	2.6	34
85	Proteomic analyses reveal that loss of TDP-43 affects RNA processing and intracellular transport. Neuroscience, 2015, 293, 157-170.	2.3	52
86	On the identification of low allele frequency mosaic mutations in the brains of Alzheimer's disease patients. Alzheimer's and Dementia, 2015, 11, 1265-1276.	0.8	57
87	Assessment of the degree of asymmetry of pathological features in neurodegenerative diseases. What is the significance for brain banks?. Journal of Neural Transmission, 2015, 122, 1499-1508.	2.8	16
88	The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients. Neurobiology of Aging, 2015, 36, 2908.e17-2908.e18.	3.1	19
89	Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathologica Communications, 2015, 3, 38.	5.2	80
90	Novel mutations support a role for Profilin 1 in the pathogenesis of ALS. Neurobiology of Aging, 2015, 36, 1602.e17-1602.e27.	3.1	87

#	Article	IF	Citations
91	Epigenomic and transcriptomic signatures of a Klinefelter syndrome (47,XXY) karyotype in the brain. Epigenetics, 2014, 9, 587-599.	2.7	53
92	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics, 2014, 23, 6139-6146.	2.9	178
93	Exome sequencing identifies 2 novel presenilin 1 mutations (p.L166V and p.S230R) in British early-onset Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2422.e13-2422.e16.	3.1	28
94	Exome-wide Rare Variant Analysis Identifies TUBA4A Mutations Associated with Familial ALS. Neuron, 2014, 84, 324-331.	8.1	308
95	Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. Nature Neuroscience, 2014, 17, 1164-1170.	14.8	488
96	Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. Neurobiology of Aging, 2014, 35, 1850-1854.	3.1	114
97	O3-04-03: CROSS-TISSUE METHYLOMIC PROFILING IN ALZHEIMER'S DISEASE. , 2014, 10, P215-P215.		0
98	Hexanucleotide Repeats in ALS/FTD Form Length-Dependent RNA Foci, Sequester RNA Binding Proteins, and Are Neurotoxic. Cell Reports, 2013, 5, 1178-1186.	6.4	419
99	Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosisâ€‹FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions. Neuropathology and Applied Neurobiology, 2013, 39, 553-561.	3.2	27
100	Neuropathology of the hippocampus in FTLDâ€Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathology and Applied Neurobiology, 2013, 39, 166-178.	3.2	54
101	The C9ORF72 expansion mutation is a common cause of ALS+/â^'FTD in Europe and has a single founder. European Journal of Human Genetics, 2013, 21, 102-108.	2.8	201
102	The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathologica, 2012, 124, 339-352.	7.7	346
103	An MND/ALS phenotype associated with C9orf72 repeat expansion: Abundant p62â€positive, TDPâ€43â€negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline. Neuropathology, 2012, 32, 505-514.	1.2	110
104	A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy. Neuropathology, 0, , .	1.2	3